These "Guidelines for Training in Cardiovascular Magnetic Resonance" were developed by the Clinical Practice Committee of the Society for Cardiovascular Magnetic Resonance (SCMR) and approved by the SCMR Board of Trustees.

Hyperphosphatemia is an independent risk factor for mortality and cardiovascular events in patients with chronic kidney disease (CKD). For patients who cannot control their serum phosphate levels adequately with diet, agents that limit gastrointestinal phosphate uptake are indicated. The use of phosphate-binding agents has changed over the years as more is learned about the mechanisms that unde...

BACKGROUND Perioperative mortality is low for patients undergoing abdominal aortic aneurysm (AAA) repair, but long-term survival remains poor. Although patients diagnosed with AAA have a significant burden of cardiovascular disease and associated risk factors, there is limited understanding of the contribution of cardiovascular risk management to long-term survival. METHODS General practice r...

OBJECTIVE Studies regularly show a higher incidence, prevalence and mortality of cardiovascular disease among immigrant groups from low-income countries. Despite residing in the Netherlands for over 60 years, the Moluccan-Dutch cardiovascular disease profile and health care use are still unknown. We aimed to compare (a) the clinical prevalence of cardiovascular diseases and (b) the use of healt...

Development of cardiovascular disease is one of the major complications of type 2 diabetes mellitus (T2DM). The chronic hyperglycaemic state is often accompanied by dyslipidaemia, hypertension, low-grade systemic inflammation and oxidative stress which collectively result in a high risk of micro- and macrovascular complications. Current glucose-lowering agents do not sufficiently address fore-m...

The pyridazine ring is present in various biologically active compounds and some pyridazine compounds have been reported as valuable cardiovascular agents. Benzimidazole-pyridazinone compound, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazole-5-yl]-5-methyl-3(2H)pyridazinone (pimobedan or vetmedin) is a potent cardiovascular agent. It is a non adrenergic, non-glycoside inotropic drug with vas...

Antiplatelet agents are increasingly being used in the management of all types of atherosclerotic disease, and, accordingly, patients on them are presenting more frequently for anaesthesia. Presentations range from elective patients taking aspirin as monotherapy for primary prevention of cardiovascular morbidity, to those maintained on multiple therapies requiring salvage surgery after a cardio...

Oncologic emergencies can present either as a progression of a known cancer or as the initial presentation of a previously undiagnosed cancer. In most of these situations, a very high degree of suspicion is required to allow prompt assessment, diagnosis, and treatment. In this article, we review the presentation and management of cardiovascular oncologic emergencies from primary and metastatic ...

(CMR) is an increasingly attractive imaging modality for the evaluation of patients with cardiovascular disease. It displays important inherent safety advantages: namely its noninvasive nature and the absence of exposure to ionizing radiation, or potentially nephrotoxic iodinated contrast agents. However, there are several potential hazards associated with magnetic resonance (MR) scanning of sp...

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that enhances glucose-stimulated insulin secretion and exerts direct and indirect actions on the cardiovascular system. GLP-1 and its related incretin hormone, glucose-dependent insulinotropic polypeptide, are rapidly inactivated by the enzyme dipeptidyl peptidase 4 (DPP-4), a key determinant of incretin bioactivity. Two classes of medicati...